Pacira BioSciences' Operating Leases fell 14.86% to $48.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $48.6 million, marking a year-over-year decrease of 14.86%. This contributed to the annual value of $44.6 million for FY2024, which is 18.54% down from last year.
Latest data reveals that Pacira BioSciences reported Operating Leases of $48.6 million as of Q3 2025, which was down 4.56% from $50.9 million recorded in Q2 2025.
Over the past 5 years, Pacira BioSciences' Operating Leases peaked at $77.7 million during Q1 2022, and registered a low of $44.6 million during Q4 2024.
For the 3-year period, Pacira BioSciences' Operating Leases averaged around $57.8 million, with its median value being $57.1 million (2024).
Its Operating Leases has fluctuated over the past 5 years, first soared by 70.23% in 2021, then fell by 18.54% in 2024.
Pacira BioSciences' Operating Leases (Quarterly) stood at $71.7 million in 2021, then dropped by 9.65% to $64.8 million in 2022, then dropped by 15.43% to $54.8 million in 2023, then declined by 18.54% to $44.6 million in 2024, then decreased by 14.86% to $48.6 million in 2025.
Its Operating Leases stands at $48.6 million for Q3 2025, versus $50.9 million for Q2 2025 and $53.1 million for Q1 2025.

Peer Comparison

Historic Data

Download Data 🔒

Date	Value